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CLASSIFICATION SYSTEM OF CHRONIC GVHD IMPACTS RISK FACTORS
Jacobs, R.W., Chen, H., Savani, B.N., Kassim, A., Clifton, C.,
Vaughan, L.A., Lucid, C.E., Jagasia, M. Vanderbilt University Medical
Center, Nashville, TN
Risk factors associated with chronic graft-versus-host-disease
(cGVHD) after allogeneic hematopoietic cell transplantation have
been studied using the limited/extensive (L/E) classification. In
2005, the NIH criteria were proposed and have been validated as
a prognostic tool in retrospective studies. It is unclear if the previ-
ously identified risk factors of cGVHD apply to cGVHD as defined
by NIH criteria. At our center, patients undergoing allo-HCT with
a survival of . 100 days are transitioned to the Long Term Trans-
plant Clinic. Grading and staging of GVHD using NIH criteria (in-
cluding severity) and L/E classification has been done prospectively
since 2006. We analyzed risk factors associated with GVHD after
day 100 and compared the factors using both classifications. Patients
characteristics are summarized in Table 1(n 5 205, cord transplant
excluded). All 11 risk factors were analyzed using univariate analysis.
Table 1. Patient characteristics
Risk Factor Variable N (205) %1 Age, median, (range) years 47 (18-70)
2 Regiment Intensity:Ablative/other 110/94 54/46
TBI*: yes/no 75/129 37/633 Gender:
Female donor-> male recipient/other 54/140 28/724 Donor Type:
Related/Unrelated 120/84V 59/41V5 Stem Cell Source:
Peripheral Blood/Bone Marrow 166/39 81/196 Disease Risk Status (CIBMTR)
Low 105 51
Intermediate 61 30
High 26 137 CMV #:
R/DU +/+ vs. other 68/130 34/668 Acute GVHD-maximum grade:
0-1 vs. 2-4 53/143 27/739 Day 100 - on steroids:
Yes/No 87/110 44/5610 Platelet count (x 10^9/L):
< 100 vs. $ 100 80/116 41/5911 Day 100 total bilirubin (mg/dL):






NIH Criteria - GVHD Classification
None 44 21
Acute subtypes 33 16




Severe 65 51*Total body irradiation, # CMV-cytomegalovirus, U R/D-recipient/
donor, v applicable for classic/overlap cGVHD only, V 37/84 unrelated
donors received in-vivo T-cell depletion.
GVHDbeyond day 100was seen in 151 of 205 patients (76%). Bonemar-
row (BM) (versus PBSC) as graft source (61% vs. 82%, P\0.001), and use
of in vivo T-cell depletion (versus no T-cell depletion) (54% vs. 84%, P\
0.0001) was associated with decreased L/E cGVHD. Using the NIH clas-
sification, BM (38% vs. 70%, P5 0.003) and in vivo T cell depletion (32%
vs. 73%, P\ 0.001) had a lower incidence of classic/overlap cGVHD
compared to no GVHD. Grade 2-4 acute GVHD (aGVHD) and use of
steroids for aGVHD at day 100 was associated with a higher incidence
of acute subtypes/noGVHDbeyondday 100 compared to classic/overlap
cGVHD (69% vs. 31%, P5 0.018; 67% vs. 33%, P5 0.052). Adjusted fordonor type, aGVHD, andday 100 steroid use, only BMas stemcell source
was an independent predictor of decreased L/E cGVHD (OR 0.37, P 5
0.017). BM as stem cell source, remained an independent factor for
decreased classic/overlap cGVHD (OR 0.3, P5 0.009). The 2 yr overall
survival (OS) for the entire cohort was 86% (95% CI, 81.6- 92). Patients
with classic/overlap cGVHD had a superior OS compared to acute
subtypes/none (P 5 0.005). Only stem cell source (BM) remained an
independent predictor of OS (HR 2.38, 95% CI 1.05-5.41, P 5 0.039).
This study shows that graft source remains an important risk
factor of cGVHD irrespective of the classification system, but the
incidence of cGVHD using the NIH criteria is significantly lower.
Other known risk factors of L/E cGVHD were not predictive of
cGVHD as defined by the NIH criteria.487
MAST CELLS SUPPRESS GVHD IN A MECHANISM INDEPENDENT OF
CD4+CD25+ REGULATORY T CELLS
Leveson-Gower, D.B.1, Sega, E.I.1, Kalesnikoff, J.2, Florek, M.1,
Galli, S.J.2, Negrin, R.S.1 1StanfordUniversity, Stanford, CA; 2Stanford
University, Stanford, CA
Mast cells, which are importantmediators of both innate and adap-
tive immune responses, have been shown to have anti-inflammatory
roles in some experimental models. Previous studies have hypothe-
sized that CD4+CD25+ regulatory T cells (Tregs) may ‘‘recruit’’
mast cells as part of a mechanism of inducing tolerance to allografts,
and also that mast cells may be able to induce CD4+ T cells into
CD4+CD25+Foxp3+ cells. In this study,we exploredwhether the sup-
pressionof graft-versus-host disease (GVHD)byTregs involvesmast
cells in a major MHC-mismatch model of GVHD. C57BL/6 (H-2b)
recipient mice were treated with myeloablative irradiation and 5x106
T-cell depleted bone marrow cells (TCD-BM) from FVB/N donors
(H-2q), followed by transfer of 2x106 FVB/NCD4 andCD8 conven-
tional T cells (Tcon) to induceGVHD.To suppress GVHD, groups
were given Treg at a Treg:Tcon ratio of 1:3. Equivalent suppression
of GVHD was observed with Treg in both wild-type C57BL/6 or
C57BL/6-KitW-sh/W-sh recipient mice (which virtually lack mast
cells), indicating that Treg suppression of GVHD in this model did
not involvemast cells. Furthermore, the percentage of Foxp3 positive
Treg cellswas similar before and after transplantation inKitW-sh/W-sh
andWT recipients, and CD4+CD25hi Treg from KitW-sh/W-sh mice
were equally capable of suppressing T cell proliferation in a mixed
leukocyte reaction. However, survival of recipients receiving TCD-
BM and Tcon only was significantly reduced in animals lacking
mast cells, where 100% of KitW-sh/W-sh recipients died by day 15 of
transplantation, yet over 50% of WT recipients were alive at day
60 (p\0.0001). While IL-10 was present at low-levels in the serum
of wild-type recipients of Tcon (mean50 pg/mL), IL-10 was
undetectable in the serum of KitW-sh/W-sh recipients. Furthermore,
preliminary experiments have indicated that KitW-sh/W-sh that have
had their gut and other sites engrafted by transfer of 5x106 bone
marrow-derived cultured mast cells (BMCMCs) i.p., have improved
survival over untreated KitW-sh/W-sh, but not if BMCMCs were de-
rived from IL-10-/- mice. Finally we observe that KitW-sh/W-sh have
greatly increased amounts ofTcon proliferation in lymph node, liver,
and gastrointestinal tract tissue sites, as indicated by bioluminescence
imaging (BLI) (p\ 0.001). Thus, we propose that the presence of
mast cells significantly reduces GVHD, independent of Treg, by
releasing IL-10 and decreasing Tcon proliferation.488
CYCLOSPORINE AND METHOTREXATE (CSA/MTX) COMPARED WITH CY-
CLOSPORINE AND MYCOPHENOLATE MOFETIL (CSA/MMF) AS GVHD
PREVENTION REGIMENS IN ALLOGENEIC STEM-CELL TRANSPLANTA-
TION FROM UNRELATED DONORS; RELATIVE OUTCOMES ARE DEPEN-
DANT ON DISEASE STATUS AT TRANSPLANTATION
Shimoni,A., Shem-Tov,N., Rand,A., Roth, S.,Volchek, Y., Yerushalmi,R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic stem cell transplantation (SCT) from matched unre-
lated donors (MUD) is a potentially curative approach in patients
(pts) with hematologic malignancies and no sibling donor. Several
GVHD prevention regimens have been used but there is no data
